These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1252299)

  • 1. Sustained release procainamide in patients with myocardial infarction.
    Birkhead J; Evans T; Mumford P; Martinez E; Jewitt D
    Br Heart J; 1976 Jan; 38(1):77-80. PubMed ID: 1252299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Oral administration of procainamide for ventricular arrhythmia. Plasma concentrations during use of tablets(Pronestyl) and a slow-release preparation (Porcainamide Durettes)].
    Bliddal J
    Ugeskr Laeger; 1976 Sep; 138(40):2425-33. PubMed ID: 968996
    [No Abstract]   [Full Text] [Related]  

  • 3. [Serum concentrations of procainamide during treatment with ordinary and sustained-release tablets].
    Henningsen P; Laursen HB; Christiansen BD; Moller J
    Ugeskr Laeger; 1976 Sep; 138(40):2433-7. PubMed ID: 968997
    [No Abstract]   [Full Text] [Related]  

  • 4. Procainamide in plasma following administration of sustained-release tablets in acute myocardial infarction.
    Ihlen H; Skomedal T; Stafsnes H; Ditlefsen EM
    Curr Ther Res Clin Exp; 1975 Mar; 17(3):257-62. PubMed ID: 805020
    [No Abstract]   [Full Text] [Related]  

  • 5. Plasma levels of procaine amide after administration of conventional and sustained-release tablets.
    Karlsson E
    Eur J Clin Pharmacol; 1973 Dec; 6(4):245-50. PubMed ID: 4591151
    [No Abstract]   [Full Text] [Related]  

  • 6. Conversion from intravenous procainamide to oral sustained release tablets in cardiac patients.
    Kalin ML; Babich MF; Klinke WP; Hui WK
    Can J Cardiol; 1990; 6(1):15-8. PubMed ID: 2310989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Procainamide in acute myocardial infarction: a study on two different tablet preparations of sustained release type.
    Ihlen H; Ditlefsen L
    Curr Ther Res Clin Exp; 1975 Nov; 18(5):720-6. PubMed ID: 812650
    [No Abstract]   [Full Text] [Related]  

  • 8. A new sustained-release tablet formulation of procainamide.
    Fremstad D; Dahl S; Jacobsen S; Lunde PK; Nådland KJ; Marthinsen AA; Waaler T; Landmark KH
    Eur J Clin Pharmacol; 1973 Dec; 6(4):251-5. PubMed ID: 4591152
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic comparisons of twice daily and four times daily formulations of procainamide in patients with frequent ventricular premature depolarization.
    Yang BB; Abel RB; Uprichard AC; Smithers JA; Forgue ST
    J Clin Pharmacol; 1996 Jul; 36(7):623-33. PubMed ID: 8844445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Procaineamide blood levels after administration of a sustained-release preparation.
    Cunningham E; Sloman G
    Med J Aust; 1977 Mar; 1(11):370-2. PubMed ID: 870815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Steady-state plasma and saliva concentrations of procainamide and N-acetyl-procainamide after a sustained release preparation].
    Pirovino M; Karlaganis G; Galeazzi RL
    Schweiz Med Wochenschr; 1980 Sep; 110(39):1415-9. PubMed ID: 6169144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experiences on a sustained-release procainamide preparation.
    Ruosteenoja R; Torsti P; Sothmann A
    Curr Ther Res Clin Exp; 1973 Oct; 15(10):707-12. PubMed ID: 4201315
    [No Abstract]   [Full Text] [Related]  

  • 13. Dosage, plasms concentration and antiarrhythmic effect of procainamide in sustained-release tablets.
    Arstila M; Katila M; Sundquist H; Anttila M; Pere E; Tikkanen R
    Acta Med Scand; 1974 Mar; 195(3):217-22. PubMed ID: 4595254
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of age, gender, and race on steady state procainamide pharmacokinetics after administration of procanbid sustained-release tablets.
    Koup JR; Abel RB; Smithers JA; Eldon MA; de Vries TM
    Ther Drug Monit; 1998 Feb; 20(1):73-7. PubMed ID: 9485559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immediate-release and sustained-release procainamide: bioavailability at steady state in cardiac patients.
    Vlasses PH; Rocci ML; Porrini KA; Greenspon AJ; Ferguson RK
    Ann Intern Med; 1983 May; 98(5 Pt 1):613-4. PubMed ID: 6189438
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetic evaluation of a sustained-release compounded procainamide preparation after 24-h (acute) administration in normal dogs.
    Thomason JD; Boothe D; KuKanich B; Rapoport G
    J Vet Cardiol; 2019 Aug; 24():58-63. PubMed ID: 31405555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absorption kinetics of procainamide in humans.
    Manion CV; Lalka D; Baer DT; Meyer MB
    J Pharm Sci; 1977 Jul; 66(7):981-4. PubMed ID: 886461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum drug concentrations in patients with ischemic heart disease after administration of a sustained release procainamide preparation.
    Zema MJ; Mirando T
    Angiology; 1983 Jan; 34(1):32-9. PubMed ID: 6186164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained-release procainamide: use of serum concentrations to determine dosage.
    Reed WE; Cooper MW
    South Med J; 1985 Oct; 78(10):1190-3. PubMed ID: 4049036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance therapy with a new retard tablet preparation of procainamide.
    Hansteen V; Landmark KH; Fremstad D; Dahl SG; Jacobsen S; Marthinsen AA; Waaler T; Frislid K; Lunde PK
    Am Heart J; 1976 Jul; 92(1):47-56. PubMed ID: 785987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.